loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in Eli Lilly releases promising early-stage data on ADC for ovarian cancer Oct 24, 2026, 10:10 AM ETEli Lilly and Company (LLY) StockBy: Jonathan Block, SA News Editor Phase 1 data on Eli Lilly's (LLY) sofetabart mipitecan (Sofe-M) found that the antibody-drug conjugate plus Avastin (bevacizumab) led to high objective response and disease control rates in individuals with platinum-sensitive ovarian cancer. Results showed that the combo led to To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Recommended For You
document fetched 2026-10-24 14:50 · canonical https://seekingalpha.com/news/4656928-eli-lilly-releases-promising-early-stage-data-adc-ovarian-cancer?feed_item_type=news